3-17岁急性淋巴细胞白血病儿童乙型肝炎疫苗加强免疫的免疫原性和安全性观察  

Immunogenicity and safety of hepatitis B vaccine booster doses among 3-17-year-old children with acute lymphoblastic leukemia:an observational study

作　　者：邓鹏飞 薛曹怡 杨天 张桦 周芬 杨丹丹 王卫平 刘文敏 高怡瑾[2] 费怡 Deng Pengfei;Xue Caoyi;Yang Tian;Zhang Hua;Zhou Fen;Yang Dandan;Wang Weiping;Liu Wenmin;Gao Yijin;Fei Yi(Pudong Institute of Preventive Medicine of Fudan University,Pudong District Center for Disease Control and Prevention,Shanghai 200136,China;Shanghai Childrens Medical Center,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China)

机构地区：[1]上海市浦东新区疾病预防控制中心复旦大学浦东预防医学研究院,上海200136 [2]上海交通大学医学院附属上海儿童医学中心,上海200127

出　　处：《中国疫苗和免疫》2023年第2期159-163,共5页Chinese Journal of Vaccines and Immunization

基　　金：浦东新区卫生健康委员会重点学科(PWZxk2022-25);浦东新区卫生健康委员会学科带头人培养计划(PWRd2020-14);浦东新区疾病预防控制中心课题(PDCDC-2021-05);上海市优秀青年人才项目(GWV-10.2-YQ38)。

摘　　要：目的探讨急性淋巴细胞白血病(Acute lymphoblastic leukemia,ALL)儿童乙型肝炎疫苗(Hepatitis B vaccine,HepB)加强免疫的免疫原性和安全性。方法在上海市某医院招募已接种3剂次HepB、乙肝表面抗体(Hepatitis B surface antibody,HBsAb)阴性且病情稳定的3-17岁ALL儿童,按0-1-6月程序接受3剂次HepB加强免疫,检测免疫前和免疫后1个月血清乙肝表面抗体(Hepatitis B surface antibody,HBsAb),观察每剂次接种后1周内不良反应,分析HBsAb阳转率、几何平均浓度(Geometric mean concentration,GMC)和不良反应发生率。结果共入组99例受试者,HepB加强免疫后HBsAb阳转率为100%;免疫后GMC为336.59(95%CI:281.66-398.30)mIU/mL,是免疫前的148.38(95%CI:141.99-155.38)倍;免疫后总不良反应发生率为1.35%(4/297),均为低热和局部红肿。结论ALL儿童在临床治疗病情稳定后HepB加强免疫的免疫原性和安全性良好。Objective To explore immunogenicity and safety of hepatitis B vaccine(HepB)booster doses in children with acute lymphoblastic leukemia(ALL).Methods We recruited 3-17-year-old children from a hospital of Shanghai who had stable ALL,had previously received 3 doses of HepB,and were negative to hepatitis B surface antibody(HBsAb).Each subject received 3 HepB booster doses in a O-1-6-month schedule.We tested sera for HBsAb before and 1 month after vaccination and observed for adverse reactions within one week after each dose to determine HBsAb seroconversion rates,geometric mean concentrations(GMCs),and incidences of adverse reactions.Results We enrolled 99 children with ALL.The HBsAb seroconversion rate after HepB booster vaccination was 100%and the GMC was 336.59(95%CI:281.66-398.30)mIU/mL,which was 148.38(95%CI:141.99-155.38)times higher than before vaccination.The overall incidence of adverse reactions following vaccination was 1.35%(4/297);all reactions consisted of low-grade fever or injection-site redness/swelling.Conclusions HepB booster vaccination in a 0-1-6 schedule was immunogenic and safe among children with ALL who were clinically stable after treatment.

关 键 词：急性淋巴细胞白血病 乙型肝炎疫苗 免疫原性 安全性 儿童 

分 类 号：R186[医药卫生—流行病学]